CytRx (NASDAQ:CYTR)‘s stock had its “buy” rating reaffirmed by stock analysts at Aegis in a report issued on Monday.CytRx Corporation (NASDAQ:CYTR) weekly performance is -18.55%. On last trading day company shares ended up $4.17. Analysts mean target price for the company is $11.00. CytRx Corporation (NASDAQ:CYTR) distance from 50-day simple moving average (SMA50) is 9.04%.
Neuralstem, Inc. (NYSE MKT:CUR) announced that two sets of data from the NSI-189 clinical trial in major depressive disorder (MDD) were reported at two recent academic conferences: American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, on June 17th, and the International College of Neuropyschopharmacology (CINP) Annual Meeting, on June 24th, 2014. NSI-189 is Neuralstem’s lead proprietary neurogenic compound. At CINP meeting, a poster presentation on quantitative EEG (qEEG) measurements, an electrophysical biomarker of depression, taken during the course of study showed that patients in the active treatment arm of the study: Neuralstem, Inc. (NYSEMKT:CUR) shares advanced 4.17% in last trading session and ended the day on $4.50. CUR return on assets is -100.60%. Neuralstem, Inc. (NYSEMKT:CUR) quarterly performance is 18.11%.
ON june 24, 2014, TG Therapeutics, Inc. (NASDAQ:TGTX), announced an agreement with Ligand Pharmaceuticals Incorporated (Nasdaq:LGND) to license exclusive global rights to develop and commercialize Ligand’s IRAK4 inhibitor research program. Interleukin-1 Receptor Associated Kinase 4, referred to as IRAK4, is a key signaling kinase that becomes inappropriately activated in tumors that carry certain oncogenic mutations of MYD88, which can be found in most patients with Waldenström’s Macroglobulinemia, a rare B-cell cancer, as well as in a sub-set of patients with Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia. Additionally, IRAK4 is a key component of signaling pathways which regulate immune and inflammatory processes suggesting that inhibition of IRAK4 may also be useful in the treatment of autoimmune related disorders. The IRAK4 program is currently in pre-clinical development. TG Therapeutics, Inc. (NASDAQ:TGTX) shares moved down -4.13% in last trading session and was closed at $9.52, while trading in range of $9.27 – $10.50. TG Therapeutics, Inc. (NASDAQ:TGTX) year to date (YTD) performance is 144.10%.
Intrexon Corp (NYSE:XON) ended the last trading day at $25.03. Company weekly volatility is calculated as 4.60% and price to cash ratio as 11.10. Intrexon Corp (NYSE:XON) showed a negative weekly performance of -2.49%.
Synthetic Biologics Inc (NYSEMKT:SYN) announced that researchers at Cedars-Sinai Medical Center (Cedars-Sinai) found that eradication of breath methane and reduction of intestinal levels of the most common methanogenic bacterium in the human gut (M. smithii) resulted in improved insulin sensitivity by up to 50 percent, and a reduction in total cholesterol and LDL cholesterol levels in pre-diabetic, obese human subjects. The findings provide preliminary evidence that the management of methane in the gut may lead to a new generation of medicines for treating Type 2 diabetes and obesity, two morbidities often linked together. Synthetic Biologics Inc (NYSEMKT:SYN) shares moved up 4.27% in last trading session and was closed at $1.71, while trading in range of $1.64 – $1.80. Synthetic Biologics Inc (NYSEMKT:SYN)year to date (YTD) performance is 11.76%.